Neurent Medical, the pioneer behind Neuromark, a minimally invasive solution to treat chronic rhinitis, has closed its oversubscribed Series C financing, raising €62.5m (US$74m) to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.
The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
“This Series C financing will support our commercial expansion and help bring Neuromark to the patients and physicians who need it most,” said CEO of Neurent Medical, Brian Shields. “In addition to expanding patient access, this investment will also enable further evidence generation across broader populations and support the continued development of our exciting pipeline offerings.”
Kyle Dempsey, partner at MVM Partners, and Cedric Moreau, partner at Sofinnova Partners, join the board.
In 2021, it raised a US$25m Series B financing led by LSP (now EQT Life Sciences) and co-led by Atlantic Bridge. Fountain Healthcare Partners also participated as a returning investor. In 2018, it raised €9.3m in a funding round led by Fountain Healthcare Partners, alongside Atlantic Bridge Capital, the Western Development Commission, Enterprise Ireland and a syndicate of US and Irish medical device sector veterans.
